McKesson Corporation (MCK)

NYSE: MCK · Real-Time Price · USD
754.76
+11.09 (1.49%)
At close: May 7, 2026, 4:00 PM EDT
752.00
-2.76 (-0.37%)
After-hours: May 7, 2026, 7:59 PM EDT
Market Cap92.45B +6.1%
Revenue (ttm)403.43B +12.4%
Net Income4.76B +44.5%
EPS38.38 +49.2%
Shares Out 122.49M
PE Ratio21.72
Forward PE17.11
Dividend$3.28 (0.43%)
Ex-Dividend DateJun 1, 2026
Volume2,020,471
Open739.90
Previous Close743.67
Day's Range729.68 - 755.85
52-Week Range637.00 - 999.00
Beta0.36
AnalystsStrong Buy
Price Target952.92 (+26.26%)
Earnings DateMay 7, 2026

About MCK

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialt... [Read more]

Sector Healthcare
Founded 1833
Employees 51,000
Stock Exchange NYSE
Ticker Symbol MCK
Full Company Profile

Financial Performance

In fiscal year 2026, McKesson's revenue was $403.43 billion, an increase of 12.36% compared to the previous year's $359.05 billion. Earnings were $4.76 billion, an increase of 44.52%.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for MCK stock is "Strong Buy." The 12-month stock price target is $952.92, which is an increase of 26.26% from the latest price.

Price Target
$952.92
(26.26% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Notable companies reporting after market close

Notable companies reporting after the market close, with earnings consensus, include Gilead (GILD), consensus $1.91… Mckesson (MCK), consensus $11.57… Cloudflare (NET), consensus 23c… Airbnb (ABNB), c...

2 hours ago - TheFly

McKesson expects 2027 profit slightly above estimates on drug distribution strength

McKesson forecast 2027 profit slightly above Wall Street expectations after beating first-quarter profit estimates ​on Thursday, as the U.S. drug distributor ‌banks on strength in its oncology and spe...

2 hours ago - Reuters

McKesson reports Q4 EPS $11.69, consensus $11.57

Reports Q4 revenue $96.3B, consensus $101.4B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipR...

2 hours ago - TheFly

McKesson sees FY27 EPS $43.80-$44.60, consensus $44.11

Sees Fy27 revenue up 5%-9%, implying $423.6B-$439.7B, consensus $442.44B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s be...

2 hours ago - TheFly

McKesson down 2% at $737 after Q4 results and FY27 guide

16:15 EDT McKesson (MCK) down 2% at $737 after Q4 results and FY27 guide Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

2 hours ago - TheFly

McKesson Earnings Call Transcript: Q4 2026

Fiscal 2026 saw double-digit growth in revenue, profit, and EPS, driven by strong specialty and oncology performance, strategic acquisitions, and disciplined capital deployment. FY 2027 guidance projects continued robust growth, with a focus on portfolio optimization and shareholder returns.

3 hours ago - Transcripts

McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at inve...

3 hours ago - Business Wire

McKesson initiated with an Outperform at William Blair

William Blair initiated coverage of McKesson (MCK) with an Outperform rating. The company has a “durable competitive moat” with specialty-led growth upside, the analyst tells investors in a research n...

9 days ago - TheFly

McKesson price target lowered to $1,000 from $1,012 at UBS

UBS lowered the firm’s price target on McKesson (MCK) to $1,000 from $1,012 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for

15 days ago - TheFly

McKesson Corporation Declares Quarterly Dividend

IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on J...

15 days ago - Business Wire

Is McKesson Stock Still A High-Conviction Compounder?

McKesson's net earnings increased at an average rate of 14.4% over the previous three years, while its earnings per share (EPS) grew by 19.6% annually in that same period. This 5.2% disparity indicate...

16 days ago - Forbes

McKesson to Sell Stake of Medical-Surgical Unit to Apollo

McKesson said Apollo affiliates agreed to buy a minority ownership interest in its medical-surgical solutions business ahead of the unit's planned spinoff.

Other symbols: APO
17 days ago - WSJ

McKesson sells minority stake in surgical supplies unit to Apollo Funds for $1.25 billion

McKesson said on Monday ‌it will sell a minority stake in its medical-surgical solutions business to investment firm ​Apollo Funds for $1.25 billion, as it prepares ​to spin off the unit through ⁠an i...

Other symbols: APO
17 days ago - Reuters

Apollo Funds to invest $1.25B to acquire 13% interest in McKesson’s MMS business

McKesson Corporation (MCK) has entered into a definitive agreement with funds managed by affiliates of Apollo (APO), under which Apollo Funds will acquire a minority ownership interest in McKesson’s M...

Other symbols: APO
17 days ago - TheFly

McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK), a leading Healthcare Services company, today announced it has entered into a definitive agreement with funds managed by affiliates of ...

17 days ago - Business Wire

McKesson target cut, added to ‘Tactical Underperform’ list at Evercore ISI

Evercore ISI lowered the firm’s price target on McKesson (MCK) to $950 from $1,000 and keeps an Outperform rating on the shares as the firm made several price target adjustments

4 weeks ago - TheFly

McKesson price target lowered to $1,000 from $1,040 at BofA

BofA analyst Allen Lutz lowered the firm’s price target on McKesson (MCK) to $1,000 from $1,040 and keeps a Buy rating on the shares. The swift decline of cash-pay GLP-1

4 weeks ago - TheFly

McKesson ideaShare 2026 Invites Independent Pharmacists to Learn, Connect and Grow

IRVING, Texas--(BUSINESS WIRE)--Registration is now open for McKesson ideaShare 2026, a premier community pharmacy event for independent pharmacy owners and their teams.

7 weeks ago - Business Wire

McKesson Transcript: Barclays 28th Annual Global Healthcare Conference

Leadership transition is underway with the CFO retiring after reaffirming guidance and overseeing the MedSurg separation. Strong financial results continue, driven by growth in pharmaceutical distribution, Oncology, and technology solutions, with stable trends in generics and specialty. Strategic focus remains on high-growth platforms and disciplined capital allocation.

2 months ago - Transcripts

McKesson Transcript: Leerink Global Healthcare Conference 2026

CFO Britt Vitalone reflected on consistent performance, specialty growth, and technology innovation, including AI and expanded services. Specialty revenues and MSO integrations are strong, while MedSurg prepares for separation. Operational efficiency and customer focus remain priorities.

2 months ago - Transcripts

McKesson Corporation Announces Fourth Quarter Fiscal 2026 Earnings Release Date and Participation in Upcoming Conferences

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Bria...

2 months ago - Business Wire

McKesson price target raised to $1,040 from $970 at BofA

BofA raised the firm’s price target on McKesson (MCK) to $1,040 from $970 and keeps a Buy rating on the shares. McKesson “quietly” received a new National Drug Code for

Other symbols: COR
2 months ago - TheFly

McKesson CFO Britt Vitalone to retire, Kenny Cheung to succeed

McKesson (MCK) announced Britt Vitalone, executive VP and CFO, has elected to retire after a 20-year career with the company, including more than eight years as CFO. Looking ahead, Kenny

Other symbols: SYY
2 months ago - TheFly

McKesson Announces Planned CFO Transition

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today announced Britt Vitalone, Executive Vice President and Chief Financial Officer (CFO), has elected to retire after a successful an...

2 months ago - Business Wire

See How Institutional Inflows Make McKesson Fly

McKesson Corporation (MCK) shares up 58% in a year thanks to Big Money.

2 months ago - FXEmpire